Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System
Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System
Not yet recruiting · NCT07721350 · Registry updated 2026-07-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not applicable | 2026-07-23 | NCT07721350 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hospices Civils de Lyon | 429 |
| KORU Medical Systems | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hôpital Lyon-Sud | Pierre-Bénite | France | 2 |